Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL627096 | 0.86 | TLR7 (0.45) | SLC6A3SLC6A4 | |
| SCHEMBL15011323 | 0.85 | GRM4 (0.47) | SLC6A3SLC6A4GRM4SLC6A2 | |
| SCHEMBL628166 | 0.83 | KDM4E (0.47) | GRM4NPSR1 | |
| SCHEMBL628363 | 0.81 | HSD11B1 (0.52) | SLC6A3GRM4 | |
| SCHEMBL626251 | 0.81 | SLC6A4 (0.43) | SLC6A3SLC6A4NPSR1SLC6A2 | |
| SCHEMBL14893836 | 0.79 | TRPV3 (0.52) | TRPV3GRM4NPSR1 | |
| SCHEMBL627876 | 0.78 | TLR7 (0.48) | SLC6A3SLC6A4GRM4SLC6A2 | |
| SCHEMBL625891 | 0.78 | SLC6A4 (0.49) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL625149 | 0.76 | SLC6A4 (0.61) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL14957234 | 0.76 | GRM4 (0.52) | TRPV3GRM4NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9156788-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2603490-A1 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012019315-A1 | NOVEL TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150409-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | TRPV3 1/4885SLC6A3 717/4885SLC6A4 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.